Literature DB >> 8102120

Relationship of antibodies against CD4+ T cells in HIV-infected patients to markers of activation and progression: autoantibodies are closely associated with CD4 cell depletion.

C Müller1, S Kukel, R Bauer.   

Abstract

Antibodies against lymphocytes have been shown in human immunodeficiency virus (HIV)-infected patients, but their relevance in the pathogenesis of acquired immune deficiency syndrome (AIDS) remains controversial. We investigated increased levels of lymphocyte surface Ig and antibodies against CD4+ T cells in the plasma. The relationship to CD4 cell depletion and serological parameters were analysed. A three-colour flow cytometric method was used to detect surface Ig on the surface of patients' cells and antibodies in the plasma of the patients. We observed a high percentage of patients with increased surface Ig on CD4+ T cells (94%-47/50). Antibodies in the plasma reacting with healthy donors' CD4+ T cells were detectable in 72% (23/32) of the patients. CD4 cell-surface Ig correlated well with surface Ig on different T-cell subpopulations but not with increased surface Ig on B cells. Only one control showed elevated surface Ig, plasma antibodies against lymphocytes were not detectable. Surface Ig levels of CD4+ T cells were closely associated with the CD4 cell number in HIV-infected patients of all stages of disease (r = -0.67, P = 0.00005). Other lymphocyte subsets' surface Ig did not show a significant association to CD4 cell depletion. Surface Ig and antibodies against CD4+ T cells were not related to levels of beta 2-microglobulin, p24 antibodies or interleukin-6 (IL-6), and did not depend on hypergammaglobulinaemia. In conclusion surface Ig on CD4+ T cells is likely to have an autoantibody origin. The high prevalence and association to CD4 depletion support the view that autoimmune phenomena could be involved in the pathogenesis of AIDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102120      PMCID: PMC1421877     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

1.  Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases.

Authors:  M Honda; K Kitamura; Y Mizutani; M Oishi; M Arai; T Okura; K Igarahi; K Yasukawa; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

2.  Ten-year follow-up of HIV infection in a haemophiliac cohort.

Authors:  C A Lee; A Phillips; J Elford; G Janossy; P Griffiths; P Kernoff
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

3.  Localization of B-cell stimulatory activity of HIV-1 to the carboxyl terminus of gp41.

Authors:  N Chirmule; V S Kalyanaraman; C Saxinger; F Wong-Staal; J Ghrayeb; S Pahwa
Journal:  AIDS Res Hum Retroviruses       Date:  1990-03       Impact factor: 2.205

4.  Detection of antilymphocyte antibody with two-color method in systemic lupus erythematosus and its heterogeneous specificities against human T-cell subsets.

Authors:  K Okudaira; H Nakai; T Hayakawa; T Kashiwado; K Tanimoto; Y Horiuchi; T Juji
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

5.  Autoantibodies against CD4- and CD8-positive T lymphocytes in HIV-infected hemophilia patients.

Authors:  V Daniel; R Weimer; K Schimpf; G Opelz
Journal:  Vox Sang       Date:  1989       Impact factor: 2.144

6.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

Authors:  D D Ho; T Moudgil; M Alam
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

7.  Presence and prognostic significance of antilymphocyte antibodies in symptomatic and asymptomatic human immunodeficiency virus infection.

Authors:  B H Dorsett; W Cronin; H L Ioachim
Journal:  Arch Intern Med       Date:  1990-05

8.  Surface immunoglobulin-positive T lymphocytes in HIV-1 infection: relationship to CD4+ lymphocyte depletion.

Authors:  B Ardman; K Mayer; J Bristol; M Ryan; M Settles; E Levy
Journal:  Clin Immunol Immunopathol       Date:  1990-08

9.  HIV-infected humans, but not chimpanzees, have circulating cytotoxic T lymphocytes that lyse uninfected CD4+ cells.

Authors:  J M Zarling; J A Ledbetter; J Sias; P Fultz; J Eichberg; G Gjerset; P A Moran
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

10.  Human immunodeficiency virus type 1-infected individuals make autoantibodies that bind to CD43 on normal thymic lymphocytes.

Authors:  B Ardman; M A Sikorski; M Settles; D E Staunton
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  4 in total

1.  Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy.

Authors:  Zhenwu Luo; Zhen Li; Lisa Martin; Zhuang Wan; Eric G Meissner; Enrique Espinosa; Hao Wu; Xiaocong Yu; Pingfu Fu; Maria Anna Julia Westerink; J Michael Kilby; Jennifer Wu; Lei Huang; Sonya L Heath; Zihai Li; Wei Jiang
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

2.  Anti-lymphocyte antibodies in plasma of HIV-1-infected patients preferentially react with MHC class II-negative T cells and are linked to antibodies against gp41.

Authors:  C Müller; S Kukel; K E Schneweis; R Bauer
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

3.  Effects of Early and Delayed Antiretroviral Therapy on Plasma Anti-CD4 Autoreactive IgG and Its Association With CD4+ T-Cell Recovery in Acute HIV-Infected Individuals.

Authors:  Aixin Song; Zhen Li; Zhenwu Luo; Xiaofan Lu; Rui Wang; Lifeng Liu; Wei Xia; Zhuang Wan; Tong Zhang; Bin Su; Wei Jiang; Hao Wu
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

4.  Association of progressive CD4(+) T cell decline in SIV infection with the induction of autoreactive antibodies.

Authors:  Takeo Kuwata; Yoshiaki Nishimura; Sonya Whitted; Ilnour Ourmanov; Charles R Brown; Que Dang; Alicia Buckler-White; Ranjini Iyengar; Jason M Brenchley; Vanessa M Hirsch
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.